Clinical trial
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
NCT01768195 is registered in ClinicalTrials.gov with Peking University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
- Lead sponsor
- Peking University
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 31, 2013
- Completion date
- December 31, 2017
- Enrollment
- 80 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.